FAP and neoplasm: A recent work of Wen et al., highlighted the potential of 177Lu-DOTA-EB-FAPI-RGD (LNC1009), a modification of LNC1007 with an Evans Blue motility to enhance tumor targeting, showed great promise for the imaging and therapy of solid tumors that are FAP+/αvβ3-, FAP/αvβ3+, or FAP+/αvβ3+ [131].